1356963-00-2

Upstream product

• 106579-00-4 5-methoxy-2-methyl-4-nitroaniline 
• 314298-13-0 1-fluoro-5-methoxy-2-methyl-4-nitro-benzene 
• 1356962-93-0 8-(5-Methoxy-2-methyl-4-nitrophenyl)-1,4-dioxa-8-azaspiro[4.5]decane 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 83341-28-0 5-fluoro-4-methyl-2-nitrophenol 
• 452-78-8 3-fluoro-4-methyl phenol 

Downstream Products

• 1356962-99-6 (R)-4-(3-fluoropyrrolidin-1-yl)-1-(5-methoxy-2-methyl-4-nitrophenyl)piperidine 
• 1356962-90-7 1-(1-(5-methoxy-2-methyl-4-nitrophenyl)piperidin-4-yl)-4-methylpiperazine 

Relevant academic research and scientific papers

DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE

Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.

Novel(1,2,4)triazolo(1,5-a)pyridylphosphine oxide and use thereof

The present invention relates to novel(1,2,4)triazolo(1,5-a)pyridinyl phosphorus oxides and uses thereof. Wherein the compound is a compound represented by a formula I, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, or a solvate thereof, or a metabolite thereof, or a stereoisomer thereof, or a tautomer thereof, or a prodrug thereof, and R1 to R5 are as defined in the specification. The compound disclosed by the invention can be used for preparing a medicine for treating and/or preventing cancers.

CHEMICAL COMPOUNDS

The present invention relates to compounds of Formula (I) and/or Formula (Ia): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit ALK kinase activity, and thus may be used for the tr